Stimulation of Immune Checkpoint Molecule B and T-Lymphocyte Attenuator Alleviates Experimental Crescentic Glomerulonephritis.
Journal
Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
received:
24
01
2023
accepted:
15
05
2023
pmc-release:
01
08
2024
medline:
2
8
2023
pubmed:
27
6
2023
entrez:
27
6
2023
Statut:
ppublish
Résumé
Treatment of acute, crescentic glomerulonephritis (GN) consists of unspecific and potentially toxic immunosuppression. T cells are central in the pathogenesis of GN, and various checkpoint molecules control their activation. The immune checkpoint molecule B and T-lymphocyte attenuator (BTLA) has shown potential for restraining inflammation in other T-cell-mediated disease models. To investigate its role in GN in a murine model of crescentic nephritis, the authors induced nephrotoxic nephritis in BTLA-deficient mice and wild-type mice. They found that BTLA has a renoprotective role through suppression of local Th1-driven inflammation and expansion of T regulatory cells and that administration of an agonistic anti-BTLA antibody attenuated experimental GN. These findings suggest that antibody-based modulation of BTLA may represent a treatment strategy in human glomerular disease. Modulating T-lymphocytes represents a promising targeted therapeutic option for glomerulonephritis (GN) because these cells mediate damage in various experimental and human GN types. The immune checkpoint molecule B and T-lymphocyte attenuator (BTLA) has shown its potential to restrain inflammation in other T-cell-mediated disease models. Its role in GN, however, has not been investigated. We induced nephrotoxic nephritis (NTN), a mouse model of crescentic GN, in Btla -deficient ( BtlaKO ) mice and wild-type littermate controls and assessed disease severity using functional and histologic parameters at different time points after disease induction. Immunologic changes were comprehensively evaluated by flow cytometry, RNA sequencing, and in vitro assays for dendritic cell and T-cell function. Transfer experiments into Rag1KO mice confirmed the observed in vitro findings. In addition, we evaluated the potential of an agonistic anti-BTLA antibody to treat NTN in vivo . The BtlaKO mice developed aggravated NTN, driven by an increase of infiltrating renal Th1 cells. Single-cell RNA sequencing showed increased renal T-cell activation and positive regulation of the immune response. Although BTLA-deficient regulatory T cells (Tregs) exhibited preserved suppressive function in vitro and in vivo , BtlaKO T effector cells evaded Treg suppression. Administration of an agonistic anti-BTLA antibody robustly attenuated NTN by suppressing nephritogenic T effector cells and promoting Treg expansion. In a model of crescentic GN, BTLA signaling effectively restrained nephritogenic Th1 cells and promoted regulatory T cells. Suppression of T-cell-mediated inflammation by BTLA stimulation may prove relevant for a broad range of conditions involving acute GN.
Sections du résumé
SIGNIFICANCE STATEMENT
Treatment of acute, crescentic glomerulonephritis (GN) consists of unspecific and potentially toxic immunosuppression. T cells are central in the pathogenesis of GN, and various checkpoint molecules control their activation. The immune checkpoint molecule B and T-lymphocyte attenuator (BTLA) has shown potential for restraining inflammation in other T-cell-mediated disease models. To investigate its role in GN in a murine model of crescentic nephritis, the authors induced nephrotoxic nephritis in BTLA-deficient mice and wild-type mice. They found that BTLA has a renoprotective role through suppression of local Th1-driven inflammation and expansion of T regulatory cells and that administration of an agonistic anti-BTLA antibody attenuated experimental GN. These findings suggest that antibody-based modulation of BTLA may represent a treatment strategy in human glomerular disease.
BACKGROUND
Modulating T-lymphocytes represents a promising targeted therapeutic option for glomerulonephritis (GN) because these cells mediate damage in various experimental and human GN types. The immune checkpoint molecule B and T-lymphocyte attenuator (BTLA) has shown its potential to restrain inflammation in other T-cell-mediated disease models. Its role in GN, however, has not been investigated.
METHODS
We induced nephrotoxic nephritis (NTN), a mouse model of crescentic GN, in Btla -deficient ( BtlaKO ) mice and wild-type littermate controls and assessed disease severity using functional and histologic parameters at different time points after disease induction. Immunologic changes were comprehensively evaluated by flow cytometry, RNA sequencing, and in vitro assays for dendritic cell and T-cell function. Transfer experiments into Rag1KO mice confirmed the observed in vitro findings. In addition, we evaluated the potential of an agonistic anti-BTLA antibody to treat NTN in vivo .
RESULTS
The BtlaKO mice developed aggravated NTN, driven by an increase of infiltrating renal Th1 cells. Single-cell RNA sequencing showed increased renal T-cell activation and positive regulation of the immune response. Although BTLA-deficient regulatory T cells (Tregs) exhibited preserved suppressive function in vitro and in vivo , BtlaKO T effector cells evaded Treg suppression. Administration of an agonistic anti-BTLA antibody robustly attenuated NTN by suppressing nephritogenic T effector cells and promoting Treg expansion.
CONCLUSIONS
In a model of crescentic GN, BTLA signaling effectively restrained nephritogenic Th1 cells and promoted regulatory T cells. Suppression of T-cell-mediated inflammation by BTLA stimulation may prove relevant for a broad range of conditions involving acute GN.
Identifiants
pubmed: 37367205
doi: 10.1681/ASN.0000000000000159
pii: 00001751-202308000-00009
pmc: PMC10400100
doi:
Substances chimiques
Immune Checkpoint Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1366-1380Subventions
Organisme : NIAID NIH HHS
ID : R01 AI113903
Pays : United States
Informations de copyright
Copyright © 2023 by the American Society of Nephrology.
Références
Suárez-Fueyo A, Bradley SJ, Klatzmann D, Tsokos GC. T cells and autoimmune kidney disease. Nat Rev Nephrol. 2017;13:329–343. doi: 10.1038/nrneph.2017.34
doi: 10.1038/nrneph.2017.34
Kurts C, Panzer U, Anders HJ, Rees AJ. The immune system and kidney disease: basic concepts and clinical implications. Nat Rev Immunol. 2013;13:738–753. doi: 10.1038/nri3523
doi: 10.1038/nri3523
Paust HJ, Turner JE, Steinmetz OM, et al. The IL-23/Th17 axis contributes to renal injury in experimental glomerulonephritis. J Am Soc Nephrol. 2009;20(5):969–979. doi: 10.1681/ASN.2008050556
doi: 10.1681/ASN.2008050556
Tipping PG, Holdsworth SR. T cells in crescentic glomerulonephritis. J Am Soc Nephrol. 2006;17(5):1253–1263. doi: 10.1681/ASN.2005091013
doi: 10.1681/ASN.2005091013
Herrnstadt GR, Steinmetz OM. The role of Treg subtypes in glomerulonephritis. Cell Tissue Res. 2021;385:293–304. doi: 10.1007/s00441-020-03359-7
doi: 10.1007/s00441-020-03359-7
Ostmann A, Paust HJ, Panzer U, et al. Regulatory T cell-derived IL-10 ameliorates crescentic GN. J Am Soc Nephrol. 2013;24(6):930–942. doi: 10.1681/ASN.2012070684
doi: 10.1681/ASN.2012070684
Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of treg-mediated T cell suppression. Front Immunol. 2012;3:51. doi: 10.3389/fimmu.2012.00051
doi: 10.3389/fimmu.2012.00051
Diefenhardt P, Nosko A, Kluger MA, et al. IL-10 receptor signaling empowers regulatory T cells to control Th17 responses and protect from GN. J Am Soc Nephrol. 2018;29(7):1825–1837. doi: 10.1681/ASN.2017091044
doi: 10.1681/ASN.2017091044
Neumann K, Ostmann A, Breda PC, et al. The co-inhibitory molecule PD-L1 contributes to regulatory T cell-mediated protection in murine crescentic glomerulonephritis. Sci Rep. 2019;9:2038. doi: 10.1038/s41598-018-38432-3
doi: 10.1038/s41598-018-38432-3
Turner JE, Paust HJ, Steinmetz OM, et al. CCR6 recruits regulatory T cells and Th17 cells to the kidney in glomerulonephritis. J Am Soc Nephrol. 2010;21(6):974–985. doi: 10.1681/ASN.2009070741
doi: 10.1681/ASN.2009070741
Nosko A, Kluger MA, Diefenhardt P, et al. T-bet enhances regulatory T cell fitness and directs control of Th1 responses in crescentic GN. J Am Soc Nephrol. 2017;28(1):185–196. doi: 10.1681/ASN.2015070820
doi: 10.1681/ASN.2015070820
Lee H-G, Cho M-Z, Choi J-M. Bystander CD4+ T cells: crossroads between innate and adaptive immunity. Exp Mol Med. 2020;52:1255–1263. doi: 10.1038/s12276-020-00486-7
doi: 10.1038/s12276-020-00486-7
Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019;20:1425–1434. doi: 10.1038/s41590-019-0512-0
doi: 10.1038/s41590-019-0512-0
Ning Z, Liu K, Xiong H. Roles of BTLA in immunity and immune disorders. Front Immunol. 2021;12:654960. doi: 10.3389/fimmu.2021.654960
doi: 10.3389/fimmu.2021.654960
Gavrieli M, Watanabe N, Loftin SK, Murphy TL, Murphy KM. Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2. Biochem Biophys Res Commun. 2003;312(4):1236–1243. doi: 10.1016/j.bbrc.2003.11.070
doi: 10.1016/j.bbrc.2003.11.070
Sedy JR, Gavrieli M, Potter KG, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol. 2005;6:90–98. doi: 10.1038/ni1144
doi: 10.1038/ni1144
Krieg C, Han P, Stone R, Goularte OD, Kaye J. Functional analysis of B and T lymphocyte attenuator engagement on CD4+ and CD8+ T cells. J Immunol. 2005;175(10):6420–6427. doi: 10.4049/jimmunol.175.10.6420
doi: 10.4049/jimmunol.175.10.6420
Oya Y, Watanabe N, Owada T, et al. Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator. Arthritis Rheum. 2008;58(8):2498–2510. doi: 10.1002/art.23674
doi: 10.1002/art.23674
Watanabe N, Gavrieli M, Sedy JR, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol. 2003;4:670–679. doi: 10.1038/ni944
doi: 10.1038/ni944
Tao R, Wang L, Han R, et al. Differential effects of B and T lymphocyte attenuator and programmed death-1 on acceptance of partially versus fully MHC-mismatched cardiac allografts. J Immunol. 2005;175(9):5774–5782. doi: 10.4049/jimmunol.175.9.5774
doi: 10.4049/jimmunol.175.9.5774
Deppong C, Degnan JM, Murphy TL, Murphy KM, Green JM. B and T lymphocyte attenuator regulates T cell survival in the lung. J Immunol. 2008;181(5):2973–2979. doi: 10.4049/jimmunol.181.5.2973
doi: 10.4049/jimmunol.181.5.2973
Kobayashi Y, Iwata A, Suzuki K, et al. B and T lymphocyte attenuator inhibits LPS-induced endotoxic shock by suppressing Toll-like receptor 4 signaling in innate immune cells. Proc Natl Acad Sci U S A. 2013;110(13):5121–5126. doi: 10.1073/pnas.1222093110
doi: 10.1073/pnas.1222093110
Bekiaris V, Šedý JR, Macauley MG, Rhode-Kurnow A, Ware CF. The inhibitory receptor BTLA controls γδ T cell homeostasis and inflammatory responses. Immunity 2013;39(6):1082–1094. doi: 10.1016/j.immuni.2013.10.017
doi: 10.1016/j.immuni.2013.10.017
Jones A, Bourque J, Kuehm L, et al. Immunomodulatory functions of BTLA and HVEM govern induction of extrathymic regulatory T cells and tolerance by dendritic cells. Immunity 2016;45(5):1066–1077. doi: 10.1016/j.immuni.2016.10.008
doi: 10.1016/j.immuni.2016.10.008
Stienne C, Virgen-Slane R, Elmén L, et al. Btla signaling in conventional and regulatory lymphocytes coordinately tempers humoral immunity in the intestinal mucosa. Cell Rep. 2022;38(12):110553. doi: 10.1016/j.celrep.2022.110553
doi: 10.1016/j.celrep.2022.110553
Zhang H, Wang Z, Zhang J, et al. Combined immunotherapy with belatacept and BTLA overexpression attenuates acute rejection following kidney transplantation. Front Immunol. 2021;12:618737. doi: 10.3389/fimmu.2021.618737
doi: 10.3389/fimmu.2021.618737
Zhang J, Zhang H, Wang Z, et al. BTLA suppress acute rejection via regulating TCR downstream signals and cytokines production in kidney transplantation and prolonged allografts survival. Sci Rep. 2019;9:12154. doi: 10.1038/s41598-019-48520-7
doi: 10.1038/s41598-019-48520-7
Oster C, Wilde B, Specker C, et al. BTLA expression on Th1, Th2 and Th17 effector T-cells of patients with systemic lupus erythematosus is associated with active disease. Int J Mol Sci. 2019;20(18):4505. doi: 10.3390/ijms20184505
doi: 10.3390/ijms20184505
Hao Y, Hao S, Andersen-Nissen E, et al. Integrated analysis of multimodal single-cell data. Cell 2021;184(13):3573–3587.e3529. doi: 10.1016/j.cell.2021.04.048
doi: 10.1016/j.cell.2021.04.048
Franzén O, Gan LM, Björkegren JLM. PanglaoDB: a web server for exploration of mouse and human single-cell RNA sequencing data. Database (Oxford). 2019;2019:baz046. doi: 10.1093/database/baz046
doi: 10.1093/database/baz046
Strimmer K. fdrtool: a versatile R package for estimating local and tail area-based false discovery rates. Bioinformatics. 2008;24(12):1461–1462. doi: 10.1093/bioinformatics/btn209
doi: 10.1093/bioinformatics/btn209
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi: 10.1186/s13059-014-0550-8
doi: 10.1186/s13059-014-0550-8
Kolberg L, Raudvere U, Kuzmin I, Vilo J, Peterson H. gprofiler2—an R package for gene list functional enrichment analysis and namespace conversion toolset g:Profiler. F1000Res 2020;9:ELIXIR-709. doi: 10.12688/f1000research.24956.2
doi: 10.12688/f1000research.24956.2
Supek F, Bošnjak M, Škunca N, Šmuc T. REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS One 2011;6:e21800. doi: 10.1371/journal.pone.0021800
doi: 10.1371/journal.pone.0021800
Albring JC, Sandau MM, Rapaport AS, et al. Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression. J Exp Med. 2010;207(12):2551–2559. doi: 10.1084/jem.20102017
doi: 10.1084/jem.20102017
Wiedemann A, Lettau M, Weißenberg SY, et al. BTLA expression and function are impaired on SLE B cells. Front Immunol. 2021;12:667991. doi: 10.3389/fimmu.2021.667991
doi: 10.3389/fimmu.2021.667991
Werner K, Dolff S, Dai Y, et al. The co-inhibitor BTLA is functional in ANCA-associated vasculitis and suppresses Th17 cells. Front Immunol. 2019;10:2843. doi: 10.3389/fimmu.2019.02843
doi: 10.3389/fimmu.2019.02843